Developing Dechra Pharmaceuticals PLC Focusing Delivering Annual Report and Accounts for the year ended 30 June 2013 Annual Report and Accounts for the year ended 30 June 2013 Stock Code: DPH ® www.dechra.com 22581-04 22/08/2013 Proof 3 ® Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2013 Developing the Business through Investment in our Pipeline The development of our product pipeline Research and is critical to our future organic growth. Development Spend Our spend has more than doubled in the last five years with an increase of almost 39% in the last financial year, taking our up 38.8% total spend to £8 million. at £8.0m (2012: £5.7m) Focusing on our Veterinary Pharmaceuticals 1 July 2000 to 1 July 2001 to 1 July 2002 to 1 July 2003 to 1 July 2004 to 1 July 2005 to 1 July 2006 to 1 July 2007 to 1 July 2008 to 1 July 2009 to 1 July 2010 to 1 July 2011 to 1 July 2012 to Product Strategy 30 June 2001 30 June 2002 30 June 2003 30 June 2004 30 June 2005 30 June 2006 30 June 2007 30 June 2008 30 June 2009 30 June 2010 30 June 2011 30 June 2012 30 June 2013 September 2000 December 2001 April 2003 December 2003 November 2004 July 2005 December 2006 January 2008 December 2008 November 2009 October 2010 January 2012 May 2013 Dechra listed on Vetoryl® launched in North Western Entered into a Granted a full EU Received approval Acquired the Acquired VetXX® VetXX integrated and Achieved mutual Acquired DermaP et® Acquired the Announced the closure the London Stock the UK Laboratories rebranded European marketing license for Felimazole to market Vetoryl in intellectual property for Holding A/S, a leading rebranded Dechra recognition of Inc., a Florida based worldwide rights of our manufacturing site Exchange at 120 pence to NationWide agreement with and granted a UK 19 major European Equidone® Gel developer, producer Veterinary Products Malaseb® in dermatological (excluding Canada) in Uldum, Denmark. per share, with a market Laboratories Janssen Animal Health, licence for a new countries and marketer of 17 European countries business, for a potential to HY-50® for a cash Skipton and Bladel sites renamed Dechra capitalisation of April 2002 allowing Janssen 2.5mg Felimazole companion animal consideration of consideration of £60 million full marketing and tablet products, for a total US$64.0 million. The 8.03 million Canadian Manufacturing Acquired North April 2007 December 2008 May 2003 distribution rights to June 2006 consideration of £61.7 February 2010 acquisition strengthened dollars Western Laboratories Felimazole and Vetoryl Acquired Leeds million Received FDA Dechra’s position as a and Cambridge Entered into a sub- Signed a development Veterinary Laboratories approval for Vetoryl in DVP UK’s logistics In July 2013 we announced the disposal of our Services Segment December 2000 in mainland Europe April 2005 leader in the worldwide Specialist Laboratory license agreement and marketing for £0.75 million the USA and finance function veterinary dermatological ® May 2012 July 2013 NVS’s semi automatic Services for a with Bioenvision Inc Granted a range agreement for Vetoryl integrated into a market namely National Veterinary Services, Dechra Laboratory Services and picking system consideration of to develop Vetoryl for extension for a 30mg in Japan with Kyoritsu central logistic and Acquired Eurovet® Announced the disposal commissioned at a £2.75 million, enabling future marketing in the Vetoryl capsule Seiyaku May 2007 May 2009 shared service centre Animal Health B.V., an of the Services Segment cost of £0.5 million Dechra to extend its USA and Canada in Uldum, Denmark expert in developing, to Patterson Companies, Dechra Specialist Laboratory Services. This completes our evolution service offering to the Secured a long term New therapeutic December 2010 registering, producing Inc for £87.5 million, trademark license and canine diet developed ® creating a clear strategic veterinary profession April 2005 Acquired Genitrix and marketing added marketing agreement and marketed to Limited, a privately value, companion and focus and transformation from a low margin UK centric services company to Opened a US with Pharmaderm aid treatment of owned veterinary farm animal veterinary operation based in Animal Health for osteoarthritis in dogs, company with a pharmaceutical April 2002 ® Kansas City a consideration of known as Specific range of products products, for a total ® an international specialist veterinary pharmaceuticals business. Felimazole launched US$5.0 million, to CJD complementary to cash consideration of in the UK supply a range of Dechra’s, for a potential €135 million April 2005 dermatological, total consideration of ophthalmic and optic £6.4 million Acquired Vetivex®, June 2009 May 2002 products to the a licensed veterinary US veterinary market Received approval Acquired Anglian fluid therapy product, to market Felimazole Underlying Operating Profit split by Services and Pharmaceuticals Pharma Plc for a for £0.8 million in USA consideration of Segments since 2005* £2.5 million which £ million more than doubled Dechra’s contract manufacturing Revenue revenues £ million Revenue 522.4 £ million Revenue Underlying Profit £11.1m £43.4m £ million 426.0 Revenue Before Taxation 389.2 Underlying Profit £ million * Revenue £ million £ million Before Taxation 44.6 369.4 Underlying Profit £ million Revenue 350.0 Before Taxation 33.0 Dividend £ million Underlying Profit £ million per Share 304.4 Underlying Profit Before Taxation 30.1 Dividend pence Revenue Before Taxation £ million per Share 14.00† £11.1m £29.0m Dividend £ million Underlying Profit £ million 26.1 pence Revenue 23.4 per Share 12.27† Revenue* 253.8 Before Taxation Dividend pence £ million £ million Dividend per Share † £13.0m £22.1m Revenue £ million 11.12 Revenue Underlying Profit 16.9 per Share pence £ million 232.5 Revenue £ million 210.3 Before Taxation pence 9.64† £13.1m £18.0m Dividend Underlying Profit £ million † £ million 186.8 per Share 8.36 Revenue 179.3 Underlying Profit Before Taxation 12.7 £12.3m £15.3m pence 170.2 Underlying Profit Before Taxation £ million £ million Underlying Profit † Before Taxation £ million Dividend 7.58 156.4 Underlying Profit Before Taxation 11.0 £ million 9.7 per Share Before Taxation £ million pence £10.8m £10.7m Dividend Underlying Profit 8.1 £ million 6.7 Dividend per Share 6.89 † Before Taxation 7.3 Dividend per Share Dividend pence £ million per Share pence † £9.5m £6.1m per Share † 5.73 5.8 Dividend pence 4.78 £8.7m £4.9m per Share pence † £4.3m £8.0m Dividend pence 3.78† 4.32 per Share 3.78† Pharmaceuticals pence 3.44† Services * From this point forward reported under IFRS. † Adjusted for the bonus element of the Rights Issue. 2005 2006 2007 2008 2009 2010 2011 2012 2013 The above financial metrics * Excludes corporate and other unallocated costs include the results of discontinued operations. 22581-04 22/08/2013 Proof 3 Delivering Sustainable Growth and Value Upon Dechra’s Stock Market Listing in 2001 the majority of the Group’s revenue and profit was derived from National Veterinary Services (a UK services and distribution business). Throughout our evolution, utilising the Services Segment’s strong cash generation, the Group has successfully evolved into a high margin, cash generative, self-funding international specialist veterinary pharmaceuticals and related products business. 1 July 2000 to 1 July 2001 to 1 July 2002 to 1 July 2003 to 1 July 2004 to 1 July 2005 to 1 July 2006 to 1 July 2007 to 1 July 2008 to 1 July 2009 to 1 July 2010 to 1 July 2011 to 1 July 2012 to 30 June 2001 30 June 2002 30 June 2003 30 June 2004 30 June 2005 30 June 2006 30 June 2007 30 June 2008 30 June 2009 30 June 2010 30 June 2011 30 June 2012 30 June 2013 September 2000 December 2001 April 2003 December 2003 November 2004 July 2005 December 2006 January 2008 December 2008 November 2009 October 2010 January 2012 May 2013 Dechra listed on Vetoryl® launched in North Western Entered into a Granted a full EU Received approval Acquired the Acquired VetXX® VetXX integrated and Achieved mutual Acquired DermaP et® Acquired the Announced the closure the London Stock the UK Laboratories rebranded European marketing license for Felimazole to market Vetoryl in intellectual property for Holding A/S, a leading rebranded Dechra recognition of Inc., a Florida based worldwide rights of our manufacturing site Exchange at 120 pence to NationWide agreement with and granted a UK 19 major European Equidone® Gel developer, producer Veterinary Products Malaseb® in dermatological (excluding Canada) in Uldum, Denmark. per share, with a market Laboratories Janssen Animal Health, licence for a new countries and marketer of 17 European countries business, for a potential to HY-50® for a cash Skipton and Bladel sites renamed Dechra capitalisation of April 2002 allowing Janssen 2.5mg Felimazole companion animal consideration of consideration of £60 million full marketing and tablet products, for a total US$64.0 million. The 8.03 million Canadian Manufacturing Acquired North April 2007 December 2008 May 2003 distribution rights to June 2006 consideration of £61.7 February 2010 acquisition strengthened dollars Western Laboratories Felimazole and Vetoryl Acquired Leeds million Received FDA Dechra’s position as a and Cambridge Entered into a sub- Signed a development Veterinary Laboratories approval for Vetoryl in DVP UK’s logistics December 2000 in mainland Europe April 2005 leader in the worldwide Specialist Laboratory license agreement and marketing for